KRAS and Miyoshi myopathy: These data are in accordance with the Trp53/KRAS-BIcγ1 mouse model (Fig. 1h and Supplementary Fig. 4), which showed that simultaneous Trp53 loss and KRASG12D cooperated to accelerate MM onset.